Moossavi Shirin, Fehr Kelsey, Maleki Hassan, Seyedpour Simin, Keshavarz-Fathi Mahdis, Tabasi Farhad, Heravi Mehrdad, Sharifian Rayka, Shafiei Golnaz, Badihian Negin, Kelishadi Roya, Nematollahi Shahrzad, Almasi Majid, Popescu Saskia, Keshavarz-Fathi Mahsa, Rezaei Nima
Department of Physiology and Pharmacology, Cumming School of Medicine, University of Calgary, Calgary, Canada.
Digestive Oncology Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
Adv Exp Med Biol. 2021;1318:575-604. doi: 10.1007/978-3-030-63761-3_32.
The disease 2019 (COVID-19) made a public health emergency in early 2020. Despite attempts for the development of therapeutic modalities, there is no effective treatment yet. Therefore, preventive measures in various settings could help reduce the burden of disease. In this chapter, the transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing COVID-19, non-pharmaceutical approaches at individual and population level, chemoprevention, immunoprevention, preventive measures in different healthcare settings and other professions, special considerations in high-risk groups, and the role of organizations to hamper the psychosocial effects will be discussed.
2019年疾病（COVID-19）在2020年初引发了突发公共卫生事件。尽管人们尝试开发治疗方法，但目前仍没有有效的治疗手段。因此，在各种环境中采取预防措施有助于减轻疾病负担。在本章中，将讨论导致COVID-19的严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的传播、个体和群体层面的非药物方法、化学预防、免疫预防、不同医疗环境及其他行业中的预防措施、高危人群的特殊考虑因素，以及组织在减轻心理社会影响方面的作用。
